1. Albertsen PC, Hanley JA, Fine J. 20year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 4: 293(17): 2095-2101.
2. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlen BJ, Johansson JE; Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 12: 352(19): 1977-1984.
3. Horninger W, Berger A, Pelzer A, Bektic J, Klocker H, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P, Bartsch G. PSA screening program and its effect on Tyrol's prostate cancer mortality rate. The American Journal of Urology Review 2005; 3(4):172-175.
4. Chan JM, Jou RM, Carroll PR. The relative impact and future burden of prostate cancer in the United States. J Urol 2004; 172(5, Pt2): 13-17.
5. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004; 172(5, Pt2): S42-47.
6. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer. 2004; 101(9): 2001-2005.
7. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004; 172(2): 508-511.
8. Ramos CG, Roehl KA, Antenor JA, Humphrey PA, Catalona WJ. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol 2004; 172(1): 137-40.
9. Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, McConnell JD, Holmes MN, Roehrborn CG. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol 2004; 171(3): 1122-1127.
10. Moore CK, Karikehalli S, Nazeer T, Fisher HA, Kaufman RP Jr, Mian BM. Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era. J Urol 2005; 173(1): 70-72.
11. Postma R, Roobol M, Schroder FH, van der Kwast TH. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer 2004; 100(5): 968-975.
12. Rabets JC, Jones JS, Patel A, Zippe CD. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 2004; 172(1): 94-97.
13. Naya Y, Ayala AG, Tamboli P, Babaian RJ. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy? Urology 2004; 63(3): 503-508.
14. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 2004; 171(3): 1089-1092.
15. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol 2004; 171(1): 204-209.
16. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350(22): 2239-2246.
17. Raaijmakers R, Blijenberg BG, Finlay JA, Rittenhouse HG, Wildhagen MF, Roobol MJ, Schroder FH. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 2004; 171(6, Pt1): 2245-2249.
18. Link RE, Shariat SF, Nguyen CV, Farr A, Weinberg AD, Morton RA, Richardson B, Bernard D, Slawin KM. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 2004; 171(6, Pt1): 2234-2238.
19. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172(4, Pt1): 1297-1301.
20. Canto EI, Singh H, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol 2004; 172(3): 900-904.
21. Roobol MJ, van der Cruijsen IW, Schroder FH. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam). Urology 2004; 63(5): 892-897; discussion 897-899.
22. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol 2004; 171(5): 1850-1854.
23. Klotz L. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 2004; 172(5, Pt2): 48-51.
24. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004; 171(4): 1520-1524.
25. Cathelineau X, Cahill D, Widmer H, Rozet F, Baumert H, Vallancien G. Transperitoneal or extraperitoneal approach for laparoscopic radical prostatectomy: a false debate over a real challenge. J Urol 2004; 171(2, Pt1): 714-716.
26. Su LM, Link RE, Bhayani SB, Sullivan W, Pavlovich CP. Nerve-sparing laparoscopic radical prostatectomy: replicating the open surgical technique. Urology 2004; 64(1):123-7.
27. Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 2004; 63(3): 528-531.
28. Freedland SJ, Presti JC Jr, Kane CJ, Aronson WJ, Terris MK, Dorey F, Amling CL; SEARCH Database Study Group. Do younger men have better biochemical outcomes after radical prostatectomy? Urology 2004; 63(3): 518-522.
29. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC jr, Trock B, Amling CL. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer 2004; 101(4): 748-53.
30. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 2004; 172(4, Pt1): 1328-1332.
31. Han M, Partin AW, Chan DY, Walsh PC. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 2004; 171(1): 23-26.
32. Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol 2004; 172(5, Pt1): 1860-1864.
33. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004; 172(5, Pt1): 1840-1844.
34. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004; 172(3): 920-922.
35. Fromont G, Cathelineau X, Rozet F, Prapotnich D, Validire P, Vallancien G. Impact of margin size on the incidence of local residual tumor after laparoscopic radical prostatectomy. J Urol 2004; 172(5, Pt1): 1845-1847.
36. Hollenbeck BK, Wei JT, Sanda MG, Dunn RL, Sandler HM. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. Urology 2004; 63(5): 946-950.
37. Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol 2004; 172(2): 515-519.
38. Flam TA, Peyromaure M, Chauveinc L, Thiounn N, Firmin F, Cosset JM, Bernard D. Post-brachytherapy transurethral resection of the prostate in patients with localized prostate cancer. J Urol 2004; 172(1): 108-111.
39. Zelefsky MJ, Moughan J, Owen J, Zietman AL, Roach M 3rd, Hanks GE. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys 2004; 59(4): 1053-1061.
40. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 2004; 171(3): 1137-1140.
41. Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60(1): 15-23.
42. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292(7): 821-827.
43. Zietman AL, DeSilvio M, Slater JD, Rossi CJ, Yonemoto LT, Slater JM, Berkey B,. Adams JA, Shipley WU. A randomized trial comparing conventional dose (70.2GyE) and high-dose (79.2GyE) conformal radiation in early stage adenocarcinoma of the prostate: Results of an interim analysis of PROG 95-09. Int J Radiat Oncol Biol Phys 2004; 60(Suppl 1): 131-132.
44. Pickett B, Ten Haken RK, Kurhanewicz J, Qayyum A, Shinohara K, Fein B, Roach M 3rd. Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2004; 59(3): 665-673.
45. Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M 3rd. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60(4): 1047-1055.
46. Zietman AL, Chung CS, Coen JJ, Shipley WU. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol 2004; 171(1): 210-214.
47. Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys 2005; 61(2): 409-414.
48. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291(11): 1325-1332.
49. Ryan CJ, Zelefsky MJ, Heller G, Regan K, Leibel SA, Scher HI, Kelly WK. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. Urology 2004; 64(1): 90-94.
50. Lee HM, Solan MJ, Lupinacci P, Gomella LG, Valicenti RK. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Urology 2004; 64(1): 84-89.
51. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171(3): 1141-1147.
52. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005; 23(4): 800-807.
53. Beer TM, Eilers KM, Garzotto M, Hsieh YC, Mori M. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer 2004; 100(4): 758-763.
54. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63(6): 1138-1142.
55. Konety BR, Eastham JA, Reuter VE, Scardino PT, Donat SM, Dalbagni G, Russo P, Herr HW, Schwartz L, Kantoff PW, Scher H, Kelly WK. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004; 171(2, Pt1): 709-713.